A Phase 1 Open-Label Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients with Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma

Multi-center, open-label, first in human (FIH) Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CARTTnMUC1 cells). The Phase 1 portion of the trial is designed to identify a dose and regimen of CARTTnMUC1 cells that can be safely administered to patients with refractory malignancies. The single arm Phase 1a expansion portion of the trial includes patients with TnMUC1+ platinum-resistant ovarian cancer.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  myeloma
• Age: - 99 Years
• Gender: All